IP Library Granted Patent US 9,655,995
Granted Patent B2
US 9,655,995 · App. 13/743,147 · Granted May 23, 2017

Nanofiber scaffolds and methods for repairing damaged cardiac tissue

Inventor: Jingwei Xie (Chesapeake, OH)
Assignee: Marshall University Research Corporation
A61L27/3882A61F2/08A61L27/18A61L27/227A61L27/24A61L27/306A61L27/32A61L27/34A61L27/3826A61L27/3834A61L27/446A61L27/54D03D15/0061D03D25/00A61L2300/406A61L2300/41A61L2300/414A61L2400/12A61L2430/20D10B2509/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,655,995
App. No.
13/743,147
Granted
May 23, 2017
Kind
B2
Abstract

Compositions are provided comprising a nanofiber scaffold that is seeded with one or more relevant cells and has a basketweave configuration that mimics the structure of a tissue, such as a cardiac tissue. Methods for treating damaged cardiac tissue in a subject are also provided and include applying an effective amount of the composition to damaged cardiac tissue. Methods for making nanofiber scaffold compositions are further provided and include electrospinning a biodegradable polymer onto a mandrel to create a mat of electrospun nanofibers, dividing the mat into nanofiber strips; and weaving the strips into a nanofiber scaffold having a basketweave configuration that mimics the structure of a tissue.

Claims (33)

1. A composition, comprising a nanofiber scaffold seeded with one or more relevant cells, the nanofiber scaffold including a plurality of electrospun nanofiber strips cut from a non-woven mat of electrospun nanofibers, the plurality of electrospun nanofiber strips arranged orthogonally to form a basketweave configuration that mimics the structure of a tissue.

2. The composition of claim 1 , wherein the relevant cells are selected from the group consisting of adult stem cells, embryonic stem cells, induced pluripotent cells, or primary cells.

3. The composition of claim 2 , wherein the relevant cells are adult stem cells.

4. The composition of claim 3 , wherein the adult stem cells are selected from the group consisting of adipose-derived stem cells, bone marrow stem cells, and cardiac stem cells.

5. The composition of claim 4 , wherein the adult stem cells are adipose-derived stem cells.

6. The composition of claim 1 , wherein the tissue is cardiac tissue.

7. The composition of claim 1 , wherein the nanofiber strips are arranged in one or more layers.

8. The composition of claim 7 , wherein the layers comprise about 1 to about 15 layers.

9. The composition of claim 1 , wherein the nanofiber strips are comprised of randomly-oriented or uniaxially-aligned nanofibers.

10. The composition of claim 1 , wherein the nanofiber strips are comprised of nanofiber yarns.

11. The composition of claim 1 , where the nanofiber scaffold is comprised of a biodegradable polymer.

12. The composition of claim 11 , wherein the biodegradable polymer is selected from the group consisting of synthetic polymers, natural polymers, and blends of synthetic and natural polymers.

13. The composition of claim 1 , wherein the nanofiber scaffold is comprised of polycaprolactone.

14. The composition of claim 1 , further comprising an extracellular matrix protein attached to the nanofiber scaffold.

15. The composition of claim 14 , wherein the extracellular matrix protein is selected from fibronectin, laminin, and collagen.

16. The composition of claim 1 , wherein the nanofiber scaffold is coated with an electrically-conductive material selected from an electrically-conductive polymer and a metal nanoparticle.

17. The composition of claim 16 , wherein the electrically-conductive material is an electrically-conductive polymer selected from the group consisting of polypyrrole, polyaniline, and poly(3,4-ethylenedioxythiophene) (PEDOT).

18. The composition of claim 16 , wherein the metal nanoparticle is a gold nanoparticle.

19. The composition of claim 1 , further comprising a growth factor attached to the nanofiber scaffold.

20. The composition of claim 19 , wherein the growth factor is selected from the group consisting of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), insulin-like growth factor (IGF), placental growth factor (PIGF), Ang1, platelet derived growth factor-BB (PDGF-BB), and transforming growth factor β (TGF-β).

21. The composition of claim 1 , further comprising a therapeutic agent attached to the nanofiber scaffold.

22. The composition of claim 21 , wherein the therapeutic agent is an anti-inflammatory agent or an antibiotic.

23. The composition of claim 1 , wherein the nanofiber scaffold is coated with hydroxyapatite, calcium phosphate, or both.

24. A method for treating damaged cardiac tissue in a subject, comprising:

providing a composition including a nanofiber scaffold seeded with one or more relevant cells, the nanofiber scaffold including a plurality of electrospun nanofiber strips cut from a non-woven mat of electrospun nanofibers, the plurality of electrospun nanofiber strips arranged orthogonally to form a basketweave configuration that mimics the structure of cardiac tissue; and

applying an effective amount of the composition to a site of the damaged cardiac tissue in the subject.

25. The method of claim 24 , wherein the relevant cells are selected from the group consisting of adipose-derived stem cells, bone marrow stem cells, and cardiac stem cells.

26. The method of claim 25 , wherein the relevant cells comprise adipose-derived stem cells.

27. The method of claim 24 , further comprising a growth factor attached to the nanofiber scaffold.

28. The method of claim 27 , wherein the growth factor is selected from the group consisting of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), insulin-like growth factor (IGF), placental growth factor (PIGF), Ang1, platelet derived growth factor-BB (PDGF-BB), and transforming growth factor β (TGF-β).

29. The method of claim 24 , further comprising a therapeutic agent attached to the nanofiber scaffold.

30. The method of claim 29 , wherein the therapeutic agent is an anti-inflammatory agent or an antibiotic.

31. The method of claim 24 , wherein applying an effective amount of the composition comprises suturing the composition to the damaged cardiac tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2015
From: XIE, JINGWEI
To: MARSHALL UNIVERSITY RESEARCH CORPORATION
Reel/Frame 034748/0173 →
Continuity (2)
Provisional Application 61586866 · Jan 16, 2012
Related Publication 20130183352A1 · Jul 18, 2013